AstraZeneca Partners Again with Daiichi Sankyo for its ADC Cancer Treatment
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 4 (Table of Contents)
Published: 3 Apr-2019
DOI: 10.3833/pdr.v2019.i4.2415 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In their fifth collaboration together, AstraZeneca and Daiichi Sankyo have partnered up to develop and commercialise the latter’s lead antibody drug conjugate therapy, trastuzumab deruxtecan (DS-8201), for the treatment of breast and gastric cancers which are connected to the HER2 gene...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS